The judge later decided on an interim hearing on April 7 when both the prosecutor and the defense lawyer will present their evidence. The court also agreed to hold the trial from June 2-4.
In March 2010, FDA approved a labeling revision for simvastatin based on interim results from an ongoing clinical trial - the Heart Protection Study 2 (HPS2).